Pfizer And Lpath To Partner On Antibody For Wet Age-Related Macular Degeneration
This article was originally published in The Pink Sheet Daily
Executive Summary
Option deal provides $14 million upfront plus cost-sharing arrangement for previously cash-strapped biotech.